中医药治疗哮喘:基于程序性细胞死亡视角的综述
该综述检索PubMed、CNKI、Scopus和Web of Science等数据库,汇总至2026年3月的在体和离体研究及临床试验,总结程序性细胞死亡在哮喘发病中的作用,并阐述中医药通过调控凋亡、自噬、铁死亡和焦亡等途径治疗哮喘的机制与理论依据。
要点
- 中医药活性成分经调控关键蛋白与信号通路抑制程序性细胞死亡,缓解哮喘气道炎症与重塑。
- 凋亡调控涉及Bax/Bcl-2/caspase-3与PI3K/Akt轴,自噬抑制涉及PI3K/Akt/mTOR通路。
- 铁死亡经GPX4/SLC7A11轴减轻,焦亡经NLRP3/caspase-1/GSDMD炎症小体阻断,坏死性凋亡研究尚有限。
核心结论
- 该综述总结程序性细胞死亡在哮喘中的作用,为中医药通过调控程序性细胞死亡干预哮喘提供理论基础。
- 综述阐明五种主要程序性细胞死亡通路中相关因子的分子机制,并概括中医药调控程序性细胞死亡治疗哮喘的干预机制与应用。
研究设计与样本
- 检索PubMed、CNKI、Scopus和Web of Science数据库,关键词包括凋亡、自噬、铁死亡、焦亡、坏死性凋亡、哮喘和中医药。
- 纳入从建库至2026年3月的在体和离体研究及临床试验,植物分类学经药用植物名称服务、中国药典和植物名录数据库于2026年3月核实。
主要发现
- 中医药通过调节关键蛋白和信号通路表达,经程序性细胞死亡调控减轻哮喘相关气道炎症和重塑等症状。
- 哮喘中中医药化合物经Bax/Bcl-2/caspase-3和PI3K/Akt信号轴调控凋亡,经抑制PI3K/Akt/mTOR通路抑制自噬。
- 中医药经GPX4/SLC7A11轴减轻铁死亡,经靶向NLRP3/caspase-1/GSDMD炎症小体阻断焦亡。
- 中医药调控坏死性凋亡治疗哮喘的研究仍有限。
关键数值与推荐
- 检索关键词为「apoptosis」「autophagy」「ferroptosis」「pyroptosis」「necroptosis」「asthma」「TCM」。
- 纳入文献类型为在体和离体研究及临床试验,时间范围为建库至2026年3月。
临床怎么用
- 中医药干预哮喘的疗效根植于肺、脾、肾失调的中医理论及药食同源等民族药理学基础。
- 临床可基于程序性细胞死亡调控机制理解中医药活性成分在哮喘气道炎症与重塑中的作用。
局限性
- 中医药调控坏死性凋亡治疗哮喘的研究仍有限。
- 综述结论指出未来研究方向与局限性,但未在摘要中详述具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Chinese medicine (TCM) is a time-honored and holistic practice that is used to treat various diseases. The extensive medicinal properties of TCM, particularly Chinese herbal medicines (CHMs), are well-established in the context of asthma treatment. The emerging concept of medicinal food homology (MFH) has focused considerable attention on the therapeutic efficacy and mechanisms of TCM in asthma treatment. AIM OF THE WORK: This review summarizes the role of programmed cell death (PCD) in asthma pathogenesis. It delineates the mechanisms and benefits of TCM in asthma treatment and presents a theoretical basis for asthma management via PCD modulation. Additionally, it offers insights into future research directions and challenges. MATERIALS AND METHODS: Pubmed, CNKI, Scopus and Web of Science databases were searched using the following keywords: "apoptosis," "autophagy," "ferroptosis," "pyroptosis," "necroptosis," "asthma," and "TCM". Articles on in vitro and in vivo studies and clinical trials from inception to March 2026 were selected for inclusion. Plant taxonomy was verified using the Medicinal Plant Names Services, Chinese Pharmacopoeia, and Plant List databases in March 2026. Contemporary research evidence integrated with TCM theory was used to summarize the mechanisms by which TCM active components suppress PCD and help manage asthma. RESULTS: TCM mitigates asthma-related symptoms such as airway inflammation and remodeling via PCD modulation by regulating the expression of key proteins and signaling pathways. Mechanistically, in asthma, TCM compounds regulate apoptosis via the Bax/Bcl-2/caspase-3 and PI3K/Akt signaling axes, suppress autophagy by inhibiting the PI3K/Akt/mTOR pathway, alleviate ferroptosis via the GPX4/SLC7A11 axis, and block pyroptosis by targeting the NLRP3/caspase-1/GSDMD inflammasome. However, research on TCM-based regulation of necroptosis asthma remains limited. The therapeutic effects of TCM interventions for asthma are deeply rooted in TCM theories on lung, spleen, and kidney dysfunction and ethnopharmacological foundations, including MFH. CONCLUSION: This review summarizes the role of PCD in asthma, furnishes a theoretical foundation for TCM-based interventions for asthma via PCD modulation, delineates the molecular mechanisms of the factors in the five primary PCD pathways, synopsizes the intervention mechanism and application of TCM in asthma treatment via PCD modulation, and presents reference concepts for the advancement of TCM interventions for asthma. The review concludes by identifying future research directions and limitations.
引用
- Yao D, Du Y, Yuan X, et al. Traditional Chinese medicine treatment of asthma: From the insight on programmed cell death. J Ethnopharmacol. 2026. PMID: 42314809. doi:10.1016/j.jep.2026.122072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。